The expression of PD-L1 on tumor cells, assessed by immunohistochemistry (IHC) from formalin-fixed paraffin-embedded (FFPE) tissue sections, is the only approved biomarker commonly used in the clinical routine to identify subgroups of patients with a higher chance of benefit from ICI [120,121]. Here, CD274 is linked to neoplasm.